COLL Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. (COLL) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $323.5K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Freund John Gordon | Director | Sell | 20 | $34.05 | $681 | 83,952 −0% of holding | |
| Freund John Gordon | Director | Sell | 4,127 | $34.54 | $142.5K | 83,972 −4.7% of holding | |
| Lurker Nancy | Director | Sell | 4,500 | $35.97 | $161.9K | 18,017 −20% of holding | |
| BOHLIN GAREN G | Director | Sell | 8,700 | $37.18 | $323.5K | 62,259 −12.3% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.